Objective
Over 600k annual new cases of breast cancer worldwide carry poor prognosis mutations in the gene PIK3CA, but since 2020 a targeted therapeutic option – PIQRAY (alpelisib) – became available, exclusively from Novartis. However, due to the still unsatisfactory response rates, the uptake by doctors and the adherence by patients has been limited. Eligibility is established at present by assessing the PIK3CA status in tumour DNA via companion diagnostic (CDx) tests (from Qiagen and Roche). However, we found that the level of expression of the PIK3CA mutations, measured in tumour RNA, associates with prognosis and is more accurate to predict the presence of the final mutated protein (the drug target).
Hence, we are developing an innovative CDx – expressPIK - that goes beyond the present ones to test the expression of mutations and correctly identify the patients who will benefit from treatment. Our higher accuracy will increase doctors’ confidence in prescribing expressPIK (profitable for expressTEC and investors), and the better response rate (beneficial to patients) will promote patient uptake and treatment adherence (profitable for Novartis).
The total global expressPIK market is over +600 K patients per year. The European Patent pending secures the use of mutation expression levels in clinical diagnosis, for treatment with PIQRAY and other drugs in clinical trials. We are validating the technology and planning to reach the MVP within a year.
Women TechEU will support developing our business knowledge and acumen, as well as provide the access to the industry and investors network we are lacking. We hope to make a change in the survivorship of breast cancer patients, whilst setting an example of female entrepreneurship in a region with high unemployment and low biotech investment.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- social sciences economics and business business and management entrepreneurship
- natural sciences biological sciences genetics mutation
- medical and health sciences clinical medicine oncology
- natural sciences biological sciences genetics RNA
- social sciences sociology social issues unemployment
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.2 - European innovation ecosystems
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-CSA - HORIZON Coordination and Support Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIE-2022-SCALEUP-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
8005-226 Faro
Portugal
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.